India, April 20 -- Shares of Clearmind Medicine Inc. (CMND) surged over 70% on Monday morning after reporting encouraging clinical data.
The stock is currently trading at $1.23, up $0.51 or 70.02%, on the Nasdaq. It opened at $1.33 after closing the previous session at $0.72. The stock has traded between $0.59 and $52.40 over the past 52 weeks.
Clearmind said its CMND-100 drug candidate met the primary safety endpoint in a Phase I/IIa trial for Alcohol Use Disorder (AUD).
The treatment showed strong tolerability with no serious adverse events, supporting further development.
The results boost confidence in its non-hallucinogenic psychedelic-based therapy pipeline.
For comments and feedback contact: editorial@rttnews.com
Published by H...